Alzheimer's DiseasePhase 1/2"MAD"NCT05363293
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
A Phase 1/2 study testing AL001 in people with Alzheimer's Disease and Healthy Non-elderly and Elderly Adults, run by Alzamend Neuro, Inc. at 2 sites in 2 countries.
Trial summary
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. Read more about this study
- Who is it for?
- Ages 50 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
- What is being tested?
- AL001
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 65 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 4 May 2022to 15 May 2023
- Phase
- Phase 1/2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Mild to moderate Alzheimer's disease (reasonably good physical health per Investigator's review of medical \& surgical history, physical examination incl. neurological examination, 12-lead ECG, vital signs, and clinical laboratory tests)
- Able to understand and provide written informed consent and able to understand and follow instructions during study as determined by Investigator
- Subject and caregiver (if accompanying subject on site) willing to follow study procedures, willing \& able to adhere to study restrictions and to be confined at the clinical research center for 16 days
- Fluent in English speaking, reading, and writing (for cognitive testing)
- Availability of medical history to provide information about the cognitive and functional level of the participant and of a qualified source such as the caregiver willing and able to provide information about the cognitive and functional level of the participant
- Males (non-vasectomized and vasectomized) must agree to use barrier contraception during the study until after Study Day 42
Show all 13Show fewer
- Females must meet criteria if childbearing for contraception or be non-childbearing
- Clinical diagnosis of dementia (neurocognitive disorder) by a qualified clinician based on the DSM-V criteria
- Considered AD Stage 2, 3, or 4 based on the FDA classification
- Mini-Mental State Examination (MMSE) score between 16 and 26, inclusive, at Screening
- Negative result to COVID-19 test at Screening and admission (performed on Day -1)
- Non-elderly (≥18 and <65 years) and elderly (≥65 and ≤80 years) male and/or female adult subjects of any gender, race or ethnicity, determined to be generally in good physical health
- Willingness to use contraceptive methods as appropriate
Who cannot join
- Clinically significant abnormalities (as determined by investigator based on medical history, physical examination, vital sign measurements, ECG findings, or clinical laboratory findings) that may affect subject safety or successful study participation
- Presence or history of any disorder that may prevent the successful completion of the study
- Other severe acute, chronic, or historical medical or psychiatric condition or laboratory abnormality or social circumstance that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in judgment of the Investigator, would make the subject inappropriate for entry into this study
- Evidence of clinically significant hematological, renal, endocrine, pulmonary, cardiovascular, dermatologic, muscular, or allergic disease or disorder (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) that may affect the safety or successful participant of the subject
- Any history or presence of gastrointestinal disease including chronic gastritis, hemorrhagic gastritis, peptic ulcers, duodenitis, diarrhea, or inflammatory bowel disease
- Any presence or history of acute or chronic liver diseases
Show all 38Show fewer
- Any post-surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the study treatment
- Any history of frequent headache or migraine
- Kidney disease (eGFR <60 mL/minute/1.73 m2)
- Uncontrolled tachy/brady arrhythmias, atrial fibrillation, or coronary heart failure
- Psychiatric or neurological illnesses (other than Alzheimer's disease), e.g., schizophrenia or other psychotic syndromes, Parkinson's disease and related movement disorders, myasthenia gravis, and seizure disorder/history of seizure disorder and/or severe head trauma (other than a single childhood febrile seizure)
- Presence of depression, except for mild depression with no acute episodes and stable condition, as determined by the Investigator
- History of untreated thyroid dysfunction that may be independently associated with cognitive impairment
- Central nervous system-related exclusions:
- any medical condition that (per investigator's judgement) would affect subject safety and scientific integrity of the study, e.g., untreated hypothyroidism (TSH >10 mIU/L) or vitamin B12 deficiency (<300 pg/mL) which may contribute to cognitive impairment, delirium, non-AD dementia and other encephalopathies
- Hachinski scale score >4 or evidence of stroke within the past 5 years
- Systemic related exclusions:
- Active cancer (except squamous cell and basal skin cancers) requiring chemo- or radiation therapy
- Positive test results for HIV, HBV, and HCV (unless quantitative PCR negative for HCV) at Screening
- Uncontrolled hypertension with a sustained blood pressure >160/100 mmHg at Screening, check-in (Day -1), and prior to the first study drug administration
- Fever (body temperature >101.4°F [38.5°C]), acute upper respiratory, or any other infections at Screening, check-in (Day -1), and prior to the first study drug administration
- Any history of drug hypersensitivity, asthma (with the exception of childhood asthma), urticaria or other severe allergic diathesis
- History of adverse - or hypersensitivity reaction to lithium, aspirin, salicylate, L-proline, or any test article excipient
- Female who is breastfeeding, pregnant according to the pregnancy test at Screening or prior to the first study drug administration, or planning to become pregnant during the study
- Magnetic resonance imaging (MRI)-related exclusion criteria (such as intracranial mass, evidence or other anatomical findings that might affect safety or causes of cognitive impairment as assessed by a qualified neurologist)
- History of drug abuse (barbiturate, amphetamine, benzodiazepine, cocaine, opiates and cannabis) within the last 12 months or a positive urine drug screen at Screening or Day -1
- Admitted alcohol abuse or history of alcohol use that may interfere with the subject's ability to comply with the protocol requirements or positive alcohol test at Screening or Day -1.
- More than moderate current alcohol consumption (subjects will be advised to consume no more than 2 units of alcohol/d and completely abstain from 72 hours prior to any visit.
- Treatment with haloperidol, antipsychotics, monoamine oxidase inhibitors, or neuromuscular blocking agents. An appropriate drug-free period will be required for washout, particularly for any especially long half-life drugs.
- Hyponatremia, defined as serum sodium laboratory value outside the standard reference range
- Suspected of having or at risk for Brugada Syndrome
- Prescribed or OTC use of a salicylate-containing product other than low-dose aspirin for cardioprotection (e.g., aspirin, bismuth sub-salicylate, salicylazosulfapyridine [sulfasalazine]) from 1 week before first dose to 1 week after last dosing; any other prescribed anticoagulant medication
- Consumption of poppy seeds or quinine (tonic water) 48 hours prior to Day 1
- Aspirin/nasal polyposis/asthma syndrome
- Participation in a clinical trial and receipt of an investigational medication within 30 days or 5 half-lives (if known), whichever is greater, prior to the first dose of the current study drug.
- Clinically significant abnormalities detected by medical history, physical examination, vital sign measurements, ECG findings, or clinical laboratory findings or any historical or present condition/ treatment that may prevent successful or safe study completion, including substance abuse, kidney disease (estimated glomerular filtration rate [eGFR] <60 mL/minute/1.73 m2) or hyponatremia
- Use of any medication on a chronic basis except an oral contraceptive, with appropriate washout of prescription, OTC, vitamins and herbal supplements
- Female pregnant or planning to be pregnant, or breastfeeding
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
About this study
Official title: A Multiple-dose, Steady-state, Double-blind, Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Mild to Moderate Alzheimer's Disease and Healthy Adult Subjects ("MAD Study")
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.
Read the detailed description
This is a Phase 1/2a, multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose (MTD) of AL001, a crystal engineered lithium-salicylate-proline lithium delivery product that in nonclinical studies was shown to enhance and prolong the pharmacokinetic (PK) profile of lithium in the brain with enhanced efficacy potential in Alzheimer's models compared to lithium carbonate.
A maximum of approximately 72 participants will be enrolled. Participants will be randomly assigned to receive study drug (active AL001) or placebo in a ratio of 6:2, respectively, with 8 patients in each dosing cohort. Placebos will be pooled and regarded as a comparative cohort for safety.
Cohorts 2a, 3a, 4a and 5a will involve 1:1 healthy non-elderly and elderly subjects; cohorts 1, 2b, 3b, 4b and 5b will involve Alzheimer's subjects. The study will consist of a screening period (Days -28 to -2), a 14-day treatment period, and a 42-day follow-up period.
- Being tested
- AL001, Placebo
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AL001Drug
Also called Alzamend AL001
a crystal engineered lithium-salicylate-proline lithium delivery product
PlaceboOther
matching placebo formulation
| Study group | Role | What they receive |
|---|---|---|
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1 | Experimental | Participants will be randomized to receive AL001. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
A total of 9 cohorts will receive 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits.
Cohort 1 will include 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) will receive the following treatment or placebo:
• Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily ×14 days, given as 3 × 210 mg AL001 capsules TID) Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2a | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID). Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3a | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 3 will be sub-divided into 2 cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 3a and 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID) Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4a | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID) Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5a | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID) Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2b | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 2b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID). Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3b | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID) Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4b | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 4b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID) Receives: Drug: AL001; Other: Placebo |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5b | Experimental | The data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated.
Cohort 5b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort:
• Cohort 5b: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID). Receives: Drug: AL001; Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.
To evaluate the safety and tolerability of AL001 in healthy subjects and patients with adverse event(s), AD, descriptive statistics will be presented by treatment group for each cohort and overall, for the following:
Proportion of participants with treatment-emergent adverse events (TEAEs)
- Proportion of participants with serious AEs
- Proportion of participants with TEAEs that lead to premature discontinuation
- Proportion of participants with abnormal values for each safety laboratory test (change from baseline)
- Proportion of participants with abnormal values for each Electrocardiogram (ECG) parameter (change from baseline in standard 12-lead ECG parameters)
For all analyses, placebo-treated subjects from each Cohort were combined (pooled) to provide a composite placebo group for all comparisons. Adverse event profiles for all treated subjects were benign as were placebo-treated subjects. No further statistical analyses were therefore appropriate.
Measured: 42 days with a 14-day treatment period
Secondary outcomes (2)
Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001
To characterize the MTD of AL001 in all subjects treated with AL001:
- Proportion of subjects in each Cohort with plasma trough measurements of lithium > 1.0 mEq/L. Subjects above these values invoke stopping rules for subsequent cohort enrollment.
Measured: 42 days with a 14-day treatment period
Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects
To characterize the MTD of AL001 in all subjects:
- Proportion of all subjects with plasma maximum concentration (Cmax) measurements for salicylate > 30 mg/dL
Measured: 42 days with a 14-day treatment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2022
- Study start4 May 2022
- Primary completion14 Apr 2023
- Study completion15 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose clinical trial to determine the safety and maximum tolerated dose of AL001.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 65 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alzamend Neuro, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Eric Sicard, MD, Principal investigator, Alzamend
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05363293
- Sponsor's protocol ID
- AL001-ALZ02
- Acronym
- "MAD"
- Status last verified
- Feb 2025
- First submitted
- 27 Apr 2022
- Last updated
- 14 May 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multiple-dose, Steady-state, Double-blind, Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Mild to Moderate Alzheimer's Disease and Healthy Adult Subjects ("MAD Study")
- ClinicalTrials.gov ID
- NCT05363293
- Acronym / sponsor ID
- "MAD" / AL001-ALZ02
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 65 participants (actual)
- Lead sponsor
- Alzamend Neuro, Inc.Industry (pharma, biotech, devices)
- Study start
- 4 May 2022 (actual)
- Primary completion
- 14 Apr 2023 (actual)
- Study completion
- 15 May 2023 (actual)
- First posted
- 5 May 2022 (actual)
- Results
- Posted 14 May 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.
Detailed description
This is a Phase 1/2a, multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose (MTD) of AL001, a crystal engineered lithium-salicylate-proline lithium delivery product that in nonclinical studies was shown to enhance and prolong the pharmacokinetic (PK) profile of lithium in the brain with enhanced efficacy potential in Alzheimer's models compared to lithium carbonate.
A maximum of approximately 72 participants will be enrolled. Participants will be randomly assigned to receive study drug (active AL001) or placebo in a ratio of 6:2, respectively, with 8 patients in each dosing cohort. Placebos will be pooled and regarded as a comparative cohort for safety.
Cohorts 2a, 3a, 4a and 5a will involve 1:1 healthy non-elderly and elderly subjects; cohorts 1, 2b, 3b, 4b and 5b will involve Alzheimer's subjects. The study will consist of a screening period (Days -28 to -2), a 14-day treatment period, and a 42-day follow-up period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 9
- Model description
- Multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose clinical trial to determine the safety and maximum tolerated dose of AL001.
| Arm | Type | Receives |
|---|---|---|
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1 | Experimental | Drug: AL001, Other: PlaceboParticipants will be randomized to receive AL001. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort. A total of 9 cohorts will receive 5 different dose levels of AL001 in multiple ascending doses under fasted conditions up to tolerability/safety limits. Cohort 1 will include 8 AD subjects. In this cohort, 6 active and 2 placebo AD subjects (as per randomization code) will receive the following treatment or placebo: • Cohort 1: 60% of 450 mg lithium carbonate equivalent of AL001 (1890 mg AL001 daily ×14 days, given as 3 × 210 mg AL001 capsules TID) |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2a | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 2a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 2a: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID). |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3a | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 3 will be sub-divided into 2 cohorts: Cohort 3a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults) and Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 3a and 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID) |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4a | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 4a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 4a: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID) |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5a | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 5a (8 healthy subjects - 4 non-elderly adults and 4 elderly adults). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 5a: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID) |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2b | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 2b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 2b: 100% 450 mg lithium carbonate equivalent of AL001 (3150 mg AL001 daily × 14 days, given as 5 × 210 mg AL001 capsules TID). |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3b | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 3b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 3b: 140% of 450 mg lithium carbonate equivalent of AL001 (4410 mg AL001 daily × 14 days, given as 7 × 210 mg AL001 capsules TID) |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4b | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 4b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 4b: 160% of 450 mg lithium carbonate equivalent of AL001 (5040 mg AL001 daily × 14 days, given as 8 × 210 mg AL001 capsules TID) |
| Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5b | Experimental | Drug: AL001, Other: PlaceboThe data from the previous cohort must be deemed safe before the next sequential cohort may be enrolled and dosing initiated. Cohort 5b (8 AD subjects). Per randomization, there will be 6 active and 2 placebo subjects in each cohort: • Cohort 5b: 200% of 450 mg lithium carbonate equivalent of AL001 (6300 mg AL001 daily × 14 days - lithium dose equivalent to that used for bipolar/affective disorders, given as 10 × 210 mg AL001 capsules TID). |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Mild to moderate Alzheimer's disease (reasonably good physical health per Investigator's review of medical \& surgical history, physical examination incl. neurological examination, 12-lead ECG, vital signs, and clinical laboratory tests)
- Able to understand and provide written informed consent and able to understand and follow instructions during study as determined by Investigator
- Subject and caregiver (if accompanying subject on site) willing to follow study procedures, willing \& able to adhere to study restrictions and to be confined at the clinical research center for 16 days
- Fluent in English speaking, reading, and writing (for cognitive testing)
- Availability of medical history to provide information about the cognitive and functional level of the participant and of a qualified source such as the caregiver willing and able to provide information about the cognitive and functional level of the participant
Key exclusion criteria (38 listed)
- Clinically significant abnormalities (as determined by investigator based on medical history, physical examination, vital sign measurements, ECG findings, or clinical laboratory findings) that may affect subject safety or successful study participation
- Presence or history of any disorder that may prevent the successful completion of the study
- Other severe acute, chronic, or historical medical or psychiatric condition or laboratory abnormality or social circumstance that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in judgment of the Investigator, would make the subject inappropriate for entry into this study
- Evidence of clinically significant hematological, renal, endocrine, pulmonary, cardiovascular, dermatologic, muscular, or allergic disease or disorder (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) that may affect the safety or successful participant of the subject
- Any history or presence of gastrointestinal disease including chronic gastritis, hemorrhagic gastritis, peptic ulcers, duodenitis, diarrhea, or inflammatory bowel disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AL001Also: Alzamend AL001a crystal engineered lithium-salicylate-proline lithium delivery product | Drug | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3a, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3b, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4a, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4b, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5a, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5b, Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2a, Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2b |
| Placebomatching placebo formulation | Other | Multiple Ascending Doses of AL001 vs. Placebo - Cohort 1, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3a, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 3b, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4a, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 4b, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5a, Multiple Ascending Doses of AL001 vs. Placebo - Cohort 5b, Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2a, Multiple Ascending Doses of AL001 vs. Placebo - Cohorts 2b |
Primary outcome
Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.
Time frame: 42 days with a 14-day treatment period
To evaluate the safety and tolerability of AL001 in healthy subjects and patients with adverse event(s), AD, descriptive statistics will be presented by treatment group for each cohort and overall, for the following: Proportion of participants with treatment-emergent adverse events (TEAEs) * Proportion of participants with serious AEs * Proportion of participants with TEAEs that lead to premature discontinuation * Proportion of participants with abnormal values for each safety laboratory test (change from baseline) * Proportion of participants with abnormal values for each Electrocardiogram (ECG) parameter (change from baseline in standard 12-lead ECG parameters) For all analyses, placebo-treated subjects from each Cohort were combined (pooled) to provide a composite placebo group for all comparisons. Adverse event profiles for all treated subjects were benign as were placebo-treated subjects. No further statistical analyses were therefore appropriate.
2 secondary outcomes
Maximum Tolerated Dose of AL001 (Lithium Component) in All Subjects Treated With AL001
Time frame: 42 days with a 14-day treatment period
Maximum Tolerated Dose of AL001 (Salicylate Component) in All AL001-treated Subjects
Time frame: 42 days with a 14-day treatment period
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Alzheimer's Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eric Sicard, MD principal investigator
Alzamend
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing AL001 in people with Alzheimer's Disease and Healthy Non-elderly and Elderly Adults, run by Alzamend Neuro, Inc. at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 May 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. (time frame: 42 days with a 14-day treatment period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2025.